The tumour is made up from several subgroups of cells (subpopulations) with different features. One of the subset actually drives the progress of the disease, the resistance to therapy and the relapse. This subset is called cancer stem cell-like cells or tumour initiating cells.
When a patient is treated and the cancer cells may be destroyed, then when the compatible diagnostic does not discover any signal, the cancer cells may consist of a population of 109 to 1012 cells. This limit defines the remission stage of a patient. At that stage only the cancer stem cells may survive and colonise into distant organs and generate metastases in time.
ONCOSTAT Test Code: 7001 – Measures the chemo-sensitivity / chemo-resistance assessment for cytotoxic drugs, monoclonal antibodies, small molecules that inhibitor specific targets (TKI etc).
ONCOSTAT PLUS Test Codes: 7003a, 7003b, 7003c
(Formerly TU Profile Plus) – Measures the chemo-sensitivity / chemo-resistance assessment for cytotoxic drugs, monoclonal antibodies, small molecules that inhibit specific targets (TKI etc) AND the assessment of natural substances and extracts for anticancer potency.
ONCOSTAT EXTRACTS Test Codes: 7002a, 7002b
(Former TU Profile Extracts) – Measures only the assessment of natural substances and plant extracts for anticancer potency.
ONCOTRACE Test Code: 7006 – Measures the concentration of CTCs and the immune-phenotype control of these cells.
ONCOTRAIL Test Code: 7007
Measures relevant markers for specific type of malignancies i.e.
- BREAST Oncotrail
- PROSTATE Oncotrail
- COLON Oncotrail
- MELANOMA Oncotrail
- LUNG Oncotrail
- SARCOMA Oncotrail
- GASTROINTESTINAL Oncotrail
IMMUNOSTAT Test Code: 7009
Profile of humoral and cellular immunity and cachexia.
This test uses specific cellular markers and cytokine production to detect the type or types of cells that are responsible for the activation or repression of the immune system of a patient.
METASTAT Test Code: 7010
Markers on CTCs that point out the potential organ for relapse.
It can help practitioners in the prognosis of metastases trends in cancer patients and guide them in the choice of appropriate chemotherapy.
Testing Options Available:
Oncocount: Provides information on the presence and the concentration of Circulating Tumor Cells (CTC’s). It enumerates only the progenitor cells that are relevant to potent relapse and recurrence of the disease.
Oncotrace: Provides information about the presence of Circulating Tumor Cells (CTC’s), Their concentration and immunophenotype, which may help identify their origin.
Oncotrail: Provides information about the presence of Circulating Tumor Cells (CTC’s) and their concentration and immunophenotype for specific types of malignancies. This test is a tailor-made test for specific type of malignancies such as breast cancer (Oncotrail R.G.C.C. for Breast), Prostate (Oncotrail for Prostate), Sarcoma etc. This test includes only markers relevant for a specific type of malignancy which make the test a good tool for follow up control.
Onconomics: Provides information about the efficacy of specific drugs on the cancer cells derived from a single patient. The method incorporates two procedures, the epigenetic analysis and the viability assays, to validate the data.
Onconomics Plus: Provides information about the efficacy of specific drugs on the cancer cells derived from a single patient. The method incorporates two procedures (epigenetic analysis and viability assays) to validate the data. The efficacy of natural biological substances or extracts on cancer cells is also referred to. The assessment is based on three methods: the direct cytotoxic effect, stimulation of the immune system and the inhibition of proliferative signals in the cancer cells.
Onconomics Extracts: Provides information about the efficacy of natural biological substances or extracts on cancer cells. The assessment is based on three methods: the direct cytotoxic effect, stimulation of the immune system and the inhibition of proliferative signals in the cancer cells.
Metastat: Markers on CTC’s that point out the potent organ for relapse. From literature, numerous markers are associated with specific tumor organ metastases.
The Metastat test is a collection of specific markers that are detected on specific organs. Cells of the primary tumor that have the ability to metastasize will express specific genes and proteins according to the organ that will metastasize, and that is given by the genetic information.
Immune Frame: Profile of humoral and cellular immunity and cachexia. This test is focusing on the status of the immune system and immunity.
CAMBISeq: (cancer analysis, mutational burden and instability sequencing) provides next generation sequencing analysis on both DNA and RNA to help predict a patient’s response to immunotherapy and to detect variants.
NOTICE TO PATIENTS
WellLab practices in the usual practitioner-referral system for pathology laboratories. Patients are highly recommended to seek the supervision and guidance of a qualified healthcare practitioner for the interpretation of any lab results and associated information. WellLab can offer assistance in locating a suitable practitioner.
RGCC CTCs Cancer Tests with WellLab: Click here to view more
Circulating Tumor Cells and their value in personalized Cancer with WellLab: Click here to view more